Kangtai Biological’s 13-valent pneumococcal vaccine obtains Türkiye’s GMP certificate and related products are expected to enter the local market

July 3, 2025  Source: drugdu 62

"/Recently, the 13-valent pneumococcal polysaccharide conjugate vaccine of Minhai Biopharmaceuticals (hereinafter referred to as Kangtai Minhai), a wholly-owned subsidiary of Kangtai Biological, obtained the GMP certification certificate issued by the Turkish Food and Drug Administration. The acquisition of this certificate indicates that the production facilities, processes, quality control and quality management systems of Minhai Biopharmaceuticals PCV13 vaccine are in compliance with Turkey's strict pharmaceutical production quality management standards, and also indicates that the product has the necessary conditions for access to the local Turkish market.

Turkey is a "crossroads" connecting the Eurasian continent, and its geographical location has significant locational advantages. The country's economic development is growing rapidly, and its GDP ranks among the top 20 in the world. In 2024, Turkey's total population will be about 85.66 million, and the number of newborns in 2023 will be about 950,000. In recent years, the country's public health level and medical expenditure have increased significantly.

As a member of the PIC/S Alliance (an authoritative international organization that promotes international consistency of GMP standards), Turkey's GMP certification has a significant influence in the field of international drug regulation. After obtaining the Turkish GMP certification, more high-quality vaccine products of Kangtai Minhai, including the 13-valent pneumococcal vaccine, are expected to enter the Turkish market in the future, laying a good foundation for the company and local partners to further expand into surrounding markets such as the Middle East and Africa, helping to promote the coordinated development of the regional vaccine industry and create a new situation of international vaccine cooperation with both economic and social benefits.

https://finance.eastmoney.com/a/202507023445727377.html

By editor
Share: 

your submission has already been received.

OK

Subscribe

Please enter a valid Email address!

Submit

The most relevant industry news & insight will be sent to you every two weeks.